Sign in or Register   Sign in or Register
  |  

Mouse Anti-AMPD2 Recombinant Antibody (2G8) (CBMAB-A2565-YC)

Provided herein is a Mouse monoclonal antibody against Human Adenosine Monophosphate Deaminase 2. The antibody can be used for immunoassay techniques, such as ELISA, WB.
See all AMPD2 antibodies
Published Data
Fig. 1 Representative immunoblots show signals obtained with anti-AMPD1, anti-AMPD2 and antiAMPD3.
...View More
Fig. 2 Representative Western blot for AMPD2 and pAMPK.
...View More

Summary

Host Animal
Mouse
Specificity
Human
Clone
2G8
Antibody Isotype
IgG2a, κ
Application
ELISA, WB

Basic Information

Immunogen
AMPD2 (NP_631895, 86 a.a. ~ 185 a.a) partial recombinant protein with GST tag.
Host Species
Mouse
Specificity
Human
Antibody Isotype
IgG2a, κ
Clonality
Monoclonal
Application Notes
The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Formulations & Storage [For reference only, actual COA shall prevail!]

Format
Liquid
Buffer
PBS, pH 7.4
Preservative
None
Concentration
Batch dependent
Storage
Store at 4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

Target

Full Name
adenosine monophosphate deaminase 2 (isoform L)
Introduction
AMPD2 is important in purine metabolism by converting AMP to IMP. The encoded protein, which acts as a homotetramer, is one of three AMP deaminases found in mammals.
Entrez Gene ID
271
UniProt ID
Q01433
Alternative Names
Adenosine Monophosphate Deaminase 2; Adenosine Monophosphate Deaminase 2 (Isoform L); EC 3.5.4.6; AMP Deaminase Isoform L; AMP Deaminase 2; AMPD Isoform L; SPG63; AMPD; PCH9;
Function
AMP deaminase plays a critical role in energy metabolism. Catalyzes the deamination of AMP to IMP and plays an important role in the purine nucleotide cycle.
Biological Process
AMP metabolic process Source: GO_Central
Cyclic purine nucleotide metabolic process Source: UniProtKB
Energy homeostasis Source: MGI
IMP biosynthetic process Source: MGI
IMP salvage Source: UniProtKB-UniPathway
Purine-containing compound salvage Source: Reactome
Cellular Location
Cytosol
Involvement in disease
Pontocerebellar hypoplasia 9 (PCH9): A form of pontocerebellar hypoplasia, a disorder characterized by structural defects of the pons and cerebellum, evident upon brain imaging. PCH9 features include severely delayed psychomotor development, progressive microcephaly, spasticity, seizures, and brain abnormalities, including brain atrophy, thin corpus callosum, and delayed myelination.
Spastic paraplegia 63, autosomal recessive (SPG63): A form of spastic paraplegia, a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body.
PTM
Methylated at Gln-6 by N6AMT1.

Abnous, K., & Storey, K. B. (2021). 5′-Adenosine monophosphate deaminase regulation in ground squirrels during hibernation. Comparative Biochemistry and Physiology Part B: Biochemistry and Molecular Biology, 253, 110543.

Orth, M. F., Gerke, J. S., Knösel, T., Altendorf‐Hofmann, A., Musa, J., Alba‐Rubio, R., ... & Grünewald, T. G. (2019). Functional genomics identifies AMPD2 as a new prognostic marker for undifferentiated pleomorphic sarcoma. International journal of cancer, 144(4), 859-867.

Scola, E., Ganau, M., Robinson, R., Cleary, M., De Cocker, L. J., Mankad, K., ... & D’Arco, F. (2019). Neuroradiological findings in three cases of pontocerebellar hypoplasia type 9 due to AMPD2 mutation: typical MRI appearances and pearls for differential diagnosis. Quantitative imaging in medicine and surgery, 9(12), 1966.

Wang, H., & Ye, S. (2019). 301 NovelmiRNA-25 inhibits AMPD2 in peripheral blood mononuclear cells of patients with systemic lupus erythematosus and represents a promising novel biomarker.

Kortüm, F., Abou Jamra, R., Alawi, M., Berry, S. A., Borck, G., Helbig, K. L., ... & Kutsche, K. (2018). Clinical and genetic spectrum of AMPD2-related pontocerebellar hypoplasia type 9. European journal of human genetics, 26(5), 695-708.

Severino, M., Zara, F., Rossi, A., & Striano, P. (2017). Teaching NeuroImages: figure of 8: the clue to the diagnosis of AMPD2 pontocerebellar hypoplasia (PCH9). Neurology, 89(14), e172-e173.

Marsh, A. P., Yap, P., Tan, T., Pope, K., White, S. M., Chong, B., ... & Lockhart, P. J. (2017). A novel AMPD2 mutation outside the AMP deaminase domain causes pontocerebellar hypoplasia type 9. Am J Med Genet A, 173, 820-823.

Ask a question We look forward to hearing from you.
0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Loading...
Have you used Mouse Anti-AMPD2 Recombinant Antibody (2G8)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...
For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Documents

Contact us

  • Tel: (USA)
  • (UK)
  • Fax:
  • Email:

Submit A Review

Go to
Compare